News
DHTRF
12.65
NaN%
--
DRI Healthcare Trust price target raised to C$22 from C$21 at Stifel
TipRanks · 04/02 15:25
DRI Healthcare (DHT.UN) Receives a Buy from Stifel Nicolaus
TipRanks · 04/01 14:15
DRI Healthcare Raises US$250 Million in Secured Notes to Refinance Debt and Support Growth
TipRanks · 03/25 18:09
DRI Healthcare Refinances Series C Preferreds With C$108.7 Million Convertible Debenture Issue
TipRanks · 03/21 02:37
Dri Healthcare Earnings Call Highlights Record Margins
TipRanks · 03/08 00:23
RBC Capital Sticks to Its Buy Rating for DRI Healthcare (DHT.UN)
TipRanks · 03/06 01:55
DRI Healthcare Trust price target raised to C$21 from C$20 at Stifel
TipRanks · 03/05 17:10
Stifel Nicolaus Remains a Buy on DRI Healthcare (DHT.UN)
TipRanks · 03/05 15:56
DRI Healthcare Trust reports Q4 results
Seeking Alpha · 03/04 17:41
DRI Healthcare Trust declares $0.11 dividend
Seeking Alpha · 03/04 07:29
DRI Healthcare Marks Record 2025 Results and Tightens Capital Structure for Multi-Year Growth
TipRanks · 03/04 01:31
DRI Healthcare Trust Refinances Preferred Securities With New Convertible Debentures
TipRanks · 03/02 14:33
DRI Healthcare Sets March 4 Call to Discuss 2025 Year-End Results
TipRanks · 02/11 21:42
Stifel Nicolaus Keeps Their Buy Rating on DRI Healthcare (DHT.UN)
TipRanks · 02/02 14:26
RBC Capital Keeps Their Buy Rating on DRI Healthcare (DHT.UN)
TipRanks · 12/13/2025 01:55
DRI Healthcare (DHT.UN) Receives a Buy from Stifel Nicolaus
TipRanks · 12/05/2025 12:46
DRI Healthcare Trust reports Q3 results
Seeking Alpha · 11/06/2025 11:17
DRI Healthcare Trust appoints Zaheed Mawani as CFO
Seeking Alpha · 09/19/2025 21:19
Weekly Report: what happened at DHTRF last week (0908-0912)?
Weekly Report · 09/15/2025 12:16
Weekly Report: what happened at DHTRF last week (0901-0905)?
Weekly Report · 09/08/2025 12:18
More
Webull provides a variety of real-time DHTRF stock news. You can receive the latest news about DRI HEALTHCARE TRUST through multiple platforms. This information may help you make smarter investment decisions.
About DHTRF
DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. It has acquired more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The Company’s products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; Vertex Pharmaceuticals; KalVista, Galderma and others.